Arnaud Scherpereel

Also affiliated with Université de Lille, Centre Hospitalier Universitaire de Lille, Centre de Recherche en Cancérologie de Lyon, Onco Lille, CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743”.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Annals of Oncology(2022)10.1016/j.annonc.2022.01.074

N/A

5.7DataRank · unranked

265 citations

Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma +15 more

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Nature Medicine(2022)10.1038/s41591-021-01655-5

N/A

0DataRank · unranked

659 citations

Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gérard Zalcman, S. Friard +38 more